Monte Rosa EBITDA vs. Operating Margin

GLUE Stock  USD 9.44  0.76  7.45%   
Based on the key profitability measurements obtained from Monte Rosa's financial statements, Monte Rosa Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Monte Rosa's ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-137.1 M
Current Value
-130.2 M
Quarterly Volatility
48.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Monte Rosa's PB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 0.85, whereas Free Cash Flow Yield is forecasted to decline to (0.23).
For Monte Rosa profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Monte Rosa to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Monte Rosa Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Monte Rosa's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Monte Rosa Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.78)
Revenue Per Share
0.221
Return On Assets
(0.28)
Return On Equity
(0.61)
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Monte Rosa Therapeutics Operating Margin vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Monte Rosa's current stock value. Our valuation model uses many indicators to compare Monte Rosa value to that of its competitors to determine the firm's financial worth.
Monte Rosa Therapeutics is rated below average in ebitda category among its peers. It is rated # 2 in operating margin category among its peers . At present, Monte Rosa's EBITDA is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Monte Rosa by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Monte Operating Margin vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Monte Rosa

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(137.09 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Monte Rosa

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(2.88) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Monte Operating Margin Comparison

Monte Rosa is currently under evaluation in operating margin category among its peers.

Monte Rosa Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Monte Rosa, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Monte Rosa will eventually generate negative long term returns. The profitability progress is the general direction of Monte Rosa's change in net profit over the period of time. It can combine multiple indicators of Monte Rosa, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-2.7 M-2.6 M
Net Interest IncomeM9.4 M
Operating Income-143.3 M-136.1 M
Net Loss-132.9 M-126.2 M
Income Before Tax-135 M-128.3 M
Total Other Income Expense Net8.3 M8.7 M
Net Loss-97.7 M-102.5 M
Net Loss-135.4 M-128.6 M
Income Tax Expense338 K354.9 K
Interest IncomeM9.4 M
Non Operating Income Net Other136.8 K143.7 K
Change To Netincome13.3 M14 M
Net Loss(2.63)(2.77)
Income Quality 0.32  0.31 
Net Income Per E B T 1.00  1.10 

Monte Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Monte Rosa. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Monte Rosa position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Monte Rosa's important profitability drivers and their relationship over time.

Use Monte Rosa in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monte Rosa position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will appreciate offsetting losses from the drop in the long position's value.

Monte Rosa Pair Trading

Monte Rosa Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Monte Rosa could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monte Rosa when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monte Rosa - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monte Rosa Therapeutics to buy it.
The correlation of Monte Rosa is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monte Rosa moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monte Rosa Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monte Rosa can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Monte Rosa position

In addition to having Monte Rosa in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Technology Thematic Idea Now

Technology
Technology Theme
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
To fully project Monte Rosa's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Monte Rosa Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Monte Rosa's income statement, its balance sheet, and the statement of cash flows.
Potential Monte Rosa investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Monte Rosa investors may work on each financial statement separately, they are all related. The changes in Monte Rosa's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Monte Rosa's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.